



Comparison of benefits and side effects of Intravitreal Triamcinolone and Intravitreal Ozurdex injections in Non infectious posterior uveitis

¹S Aazem, ¹S Tarin

¹Wolverhampton Eye Infirmary, New Cross Hospital, Wolverhampton, WV10 0QP

Background

We looked at the two intravitreal treatments for non infective posterior uveitis. Triamcinolone comes in 4mg in 0.1ml. It's unlicensed for ocular use. This was used widely until NICE approval of Ozurdex in 2017. Ozurdex® (Allergan Pharmaceuticals) is a biodegradable ophthalmic implant that contains dexamethasone 700 micrograms. Our focus is on local treatment because of the systemic side effects of immunosuppression.

Aims

- To compare the benefits and side effects of intravitreal triamcinolone (IVTA) and intravitreal ozurdex in posterior non infective uveitis.
- To identify any IOP or CMO related trends.

Methods

- Retrospective case review where we made an objective assessment pre and post injection for Vision, CMO and IOP for patients undergoing intravitreal treatment at Week 4-6 and Month 3.
- Patients for IVTA identified from theatre register (2014-15) and Ozurdex from Blueteq register (2018-19)
- Treatment naïve- 8 eyes in each group
- 14 eyes started on Triamcinolone and moved to Ozurdex during follow up
- Fewer Ozurdex because of follow up loss due to pandemic
- Disease entity- idiopathic 20, sarcoid 6, latent TB 2, ankylosing spondylitis 1, Bechet's disease 1.

Results

R:L 13:17


M:F 17:13

Average age at 1st injection 58 years (28- 86 yrs.)


Previous treatments in year leading to injection					
Systemic therapy			Ocular therapy		
N22	IVTA	Ozurdex	N22	IVTA	Ozurdex
Oral Prednisolone	17	7	Sub tenon's Triamcinolone	4	2
IV methylprednisolone	1	-	Orbital floor Triamcinolone	4	1
Mycophenolate	5	2			
Azathioprine	1	1			
Cyclosporin	1	3			
Tacrolimus	2	-			

Vision					
IVTA N8			Ozurdex N8		
Pre Injection	4-6 weeks	3 months	Pre injection	4-6 weeks	3months
6/36	6/36	6/24	HM	6/36	6/9
6/18	6/12	6/12	6/24	6/12	6/9
6/18	6/9	6/6	6/36	6/18	6/12
6/24	6/12	6/12	6/36	6/12	6/12
6/24	CF	6/36	6/36	6/36	6/36
6/9	6/6	6/9	6/18	6/18	6/18
6/12	6/12	-	6/24	6/18	6/24
6/12	6/18	6/24	6/18	6/18	6/24

More pts in Ozurdex group improved or maintained vision vs IVTA



CMO resolution at week 4-6:
Ozurdex 75% vs IVTA 68%



Higher CMO recurrence rate in IVTA group at Month 9

	IVTA (N22)	Ozurdex (N8)
6 month	6 (27%)	2 (25%)
9 months	9 (41%)	1 (12.5%)
12 months	8 (36%)	1 (12.5%)

IVTA group had higher rate of injections at Month 9 and 12.

IOP			Surgical management		
Medical management: IOP more than 25			Trabeculectomy		
Drops	IVTA (N22)	Ozurdex (N8)	IVTA (N8)	Ozurdex (N8)	
4-6 weeks	3 (13.6%)	1 (12.5%)	3 months	2	-
			12 months	1	-
			12-24 months	1	-
Who were not on any baseline treatment					

Surgical management of IOP was only required in IVTA group

No financial disclosures. Acknowledge S Naqvi (F2) in data collection

Conclusions

Intravitreal Ozurdex had better CMO resolution with lower recurrence rate and better IOP profile compared to intravitreal Triamcinolone in our patient cohort.

References

HURON Study Group. Dexamethasone Intravitreal Implant for Non-infectious Intermediate or Posterior Uveitis. *ArchOphthalmol.* 2011;129(5):545-553. doi:10.1001/archophthalmol.2010.339